ParkinsonCanadaV1, Main, Exploration, bibRecord, 003310

Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials

Identifieur interne : 003310 ( Main/Exploration ); précédent : 003309; suivant : 003311

Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials

Auteurs : Mahyar Etminan [Canada] ; Ali Samii [États-Unis] ; Bahi Takkouche [Espagne] ; Paula A. Rochon [Canada]

Source :

Drug safety [ 0114-5916 ] ; 2001.

RBID : Pascal:02-0037951

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Pramipexole, Ropinirole, Antiparkinsonien, Chimiothérapie, Traitement, Somnolence, Homme, Toxicité, Métaanalyse, Essai clinique, Stimulant dopaminergique, Agoniste, Récepteur dopaminergique D2, Récepteur dopaminergique D3.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Agonist, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Benzothiazoles, Chemotherapy, Clinical trial, D2 Dopamine receptor, D3 Dopamine receptor, Disorders of Excessive Somnolence (chemically induced), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dopamine agonist, Drug Therapy, Combination, Human, Humans, Indoles (adverse effects), Indoles (therapeutic use), Levodopa (adverse effects), Levodopa (therapeutic use), MEDLINE, Metaanalysis, Parkinson Disease (drug therapy), Parkinson disease, Pramipexole, Randomized Controlled Trials as Topic, Risk Factors, Ropinirole, Somnolence, Thiazoles (adverse effects), Thiazoles (therapeutic use), Toxicity, Treatment.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Indoles, Levodopa, Thiazoles.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Indoles, Levodopa, Thiazoles.
- chemical : Benzothiazoles.
- chemically induced : Disorders of Excessive Somnolence.
- drug therapy : Parkinson Disease.
- Drug Therapy, Combination, Humans, MEDLINE, Randomized Controlled Trials as Topic, Risk Factors.

Abstract

Background: Recent case reports and letters have alerted practitioners to the risk of sleep attacks, usually preceded by somnolence, in patients with Parkinson's disease treated with pramipexole and ropinirole. Objective: To quantify the risk of somnolence with the new dopamine agonists pramipexole and ropinirole in patients with Parkinson's disease. Methods: We searched MEDLINE, EMBASE, International Pharmaceutical Abstracts and Cochrane Library, contacted experts and pharmaceutical manufacturers, and manually reviewed all references retrieved to identify possible articles to include. Information on randomisation, blinding, type of treatment and reporting of somnolence were abstracted by 2 independent reviewers. Disagreements were resolved by a third author. Analysis: We made 2 separate analyses. The first analysis compared the risk of somnolence in patients taking either pramipexole or ropinirole to that in patients taking placebo. The second analysis compared the risk of somnolence with these drugs (plus levodopa) versus that with levodopa alone. We calculated pooled relative risk estimates using the random effects model and when no heterogeneity was detected we used the fixed effects model. Results: Four trials were included in the analysis of patients taking pramipexole or ropinirole compared with those taking placebo. The pooled relative risk of somnolence in this analysis was 4.98 [95% confidence interval (CI) 1.79 to 13.89]. Seven trials were included in the analysis of patients taking levodopa and pramipexole or ropinirole compared with those taking levodopa alone. The pooled relative risk was 2.06 (95% CI 1.47 to 2.88). Conclusion: Patients with Parkinson's disease using pramipexole or ropinirole are at higher risk of experiencing somnolence relative to patients taking placebo. Patients taking levodopa plus either one of these dopamine agonists are at higher risk than those taking levodopa alone. Clinicians should carefully weigh this risk against the benefit of these agents when prescribing these drugs.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials</title>
<author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Pharmacy, Baycrest Center for Geriatric Care</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Clinical Epidemiology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Neurology, School of Medicine, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
<author><name sortKey="Takkouche, Bahi" sort="Takkouche, Bahi" uniqKey="Takkouche B" first="Bahi" last="Takkouche">Bahi Takkouche</name>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Preventive Medicine, Faculty of Medicine, University of Santiago de Compostela</s1>
<s2>Santiago de Compostela</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<placeName><settlement type="city">Santiago de Compostela</settlement>
<region nuts="2" type="region">Galice</region>
</placeName>
<orgName type="university">Université de Saint-Jacques-de-Compostelle</orgName>
</affiliation>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Pharmacy, Baycrest Center for Geriatric Care</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Departments of Medicine and Public Health Sciences, Faculty of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Institute for Clinical Evaluative Sciences, Sunnybrook and Women's College Health Sciences Centre</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0037951</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 02-0037951 INIST</idno>
<idno type="RBID">Pascal:02-0037951</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C07</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000116</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000A89</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000A89</idno>
<idno type="wicri:doubleKey">0114-5916:2001:Etminan M:increased:risk:of</idno>
<idno type="wicri:Area/Main/Merge">003796</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11665873</idno>
<idno type="wicri:Area/PubMed/Corpus">001592</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001592</idno>
<idno type="wicri:Area/PubMed/Curation">001592</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001592</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001592</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001592</idno>
<idno type="wicri:Area/Ncbi/Merge">000191</idno>
<idno type="wicri:Area/Ncbi/Curation">000191</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000191</idno>
<idno type="wicri:doubleKey">0114-5916:2001:Etminan M:increased:risk:of</idno>
<idno type="wicri:Area/Main/Merge">003580</idno>
<idno type="wicri:Area/Main/Curation">003310</idno>
<idno type="wicri:Area/Main/Exploration">003310</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials</title>
<author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Pharmacy, Baycrest Center for Geriatric Care</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Clinical Epidemiology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Department of Neurology, School of Medicine, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
<author><name sortKey="Takkouche, Bahi" sort="Takkouche, Bahi" uniqKey="Takkouche B" first="Bahi" last="Takkouche">Bahi Takkouche</name>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Preventive Medicine, Faculty of Medicine, University of Santiago de Compostela</s1>
<s2>Santiago de Compostela</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<placeName><settlement type="city">Santiago de Compostela</settlement>
<region nuts="2" type="region">Galice</region>
</placeName>
<orgName type="university">Université de Saint-Jacques-de-Compostelle</orgName>
</affiliation>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Pharmacy, Baycrest Center for Geriatric Care</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Departments of Medicine and Public Health Sciences, Faculty of Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Institute for Clinical Evaluative Sciences, Sunnybrook and Women's College Health Sciences Centre</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Drug safety</title>
<title level="j" type="abbreviated">Drug saf.</title>
<idno type="ISSN">0114-5916</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Drug safety</title>
<title level="j" type="abbreviated">Drug saf.</title>
<idno type="ISSN">0114-5916</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Benzothiazoles</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>D2 Dopamine receptor</term>
<term>D3 Dopamine receptor</term>
<term>Disorders of Excessive Somnolence (chemically induced)</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dopamine agonist</term>
<term>Drug Therapy, Combination</term>
<term>Human</term>
<term>Humans</term>
<term>Indoles (adverse effects)</term>
<term>Indoles (therapeutic use)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>MEDLINE</term>
<term>Metaanalysis</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Pramipexole</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Risk Factors</term>
<term>Ropinirole</term>
<term>Somnolence</term>
<term>Thiazoles (adverse effects)</term>
<term>Thiazoles (therapeutic use)</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Levodopa</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Levodopa</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Benzothiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Disorders of Excessive Somnolence</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>MEDLINE</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Pramipexole</term>
<term>Ropinirole</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Somnolence</term>
<term>Homme</term>
<term>Toxicité</term>
<term>Métaanalyse</term>
<term>Essai clinique</term>
<term>Stimulant dopaminergique</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Récepteur dopaminergique D3</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Recent case reports and letters have alerted practitioners to the risk of sleep attacks, usually preceded by somnolence, in patients with Parkinson's disease treated with pramipexole and ropinirole. Objective: To quantify the risk of somnolence with the new dopamine agonists pramipexole and ropinirole in patients with Parkinson's disease. Methods: We searched MEDLINE, EMBASE, International Pharmaceutical Abstracts and Cochrane Library, contacted experts and pharmaceutical manufacturers, and manually reviewed all references retrieved to identify possible articles to include. Information on randomisation, blinding, type of treatment and reporting of somnolence were abstracted by 2 independent reviewers. Disagreements were resolved by a third author. Analysis: We made 2 separate analyses. The first analysis compared the risk of somnolence in patients taking either pramipexole or ropinirole to that in patients taking placebo. The second analysis compared the risk of somnolence with these drugs (plus levodopa) versus that with levodopa alone. We calculated pooled relative risk estimates using the random effects model and when no heterogeneity was detected we used the fixed effects model. Results: Four trials were included in the analysis of patients taking pramipexole or ropinirole compared with those taking placebo. The pooled relative risk of somnolence in this analysis was 4.98 [95% confidence interval (CI) 1.79 to 13.89]. Seven trials were included in the analysis of patients taking levodopa and pramipexole or ropinirole compared with those taking levodopa alone. The pooled relative risk was 2.06 (95% CI 1.47 to 2.88). Conclusion: Patients with Parkinson's disease using pramipexole or ropinirole are at higher risk of experiencing somnolence relative to patients taking placebo. Patients taking levodopa plus either one of these dopamine agonists are at higher risk than those taking levodopa alone. Clinicians should carefully weigh this risk against the benefit of these agents when prescribing these drugs.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Espagne</li>
<li>États-Unis</li>
</country>
<region><li>Galice</li>
<li>Ontario</li>
<li>Washington (État)</li>
</region>
<settlement><li>Santiago de Compostela</li>
<li>Seattle</li>
<li>Toronto</li>
</settlement>
<orgName><li>Université de Saint-Jacques-de-Compostelle</li>
<li>Université de Toronto</li>
<li>Université de Washington</li>
</orgName>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
</noRegion>
<name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
<name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
<name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
</country>
<country name="États-Unis"><region name="Washington (État)"><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
</region>
</country>
<country name="Espagne"><region name="Galice"><name sortKey="Takkouche, Bahi" sort="Takkouche, Bahi" uniqKey="Takkouche B" first="Bahi" last="Takkouche">Bahi Takkouche</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003310 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003310 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:02-0037951
   |texte=   Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials

Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.